EnBioTec And Timtec Inc. Entered Into Agreement To Develop Nuclear Receptor Based Lead Chemicals

Published: Sep 11, 2006

Tokyo, Japan - EnBioTec Laboratories Co., Ltd. based in Tokyo Japan has entered into an agreement with TimTec Inc. to co-develop nuclear receptor based lead compounds for drug discovery. EnBioTec Laboratories has developed Receptor Cofactor Assay System (RCAS) to evaluate interaction between nuclear hormone receptor and co-factor in the presence of compound. The system is cell-free and highly sensitive, and is able to distinguish between agonist and antagonist.

Back to news